14 results
8-K
EX-99.1
NGM
Ngm Biopharmaceuticals Inc
11 Mar 24
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
4:13pm
, is designed to block GDF15 signaling, the central cause of HG and, thereby, may potentially have therapeutic benefit for treating pregnant women suffering … from HG. HG is a rare, serious condition that affects approximately 100,000 – 150,000 women in the United States each year during pregnancy
10-K
bbooe0062du
17 Mar 20
Annual report
4:33pm
424B1
va2nmhhhkqq8rf2dnep
4 Apr 19
Prospectus with pricing info
5:21pm
S-1/A
3q7iq 6451lj0
25 Mar 19
IPO registration (amended)
12:00am
S-1
67fwy55ts84o
28 Sep 18
IPO registration
5:14pm
DRS
2cp0xk7soh9 oe03b4iw
10 Aug 18
Draft registration statement
12:00am
- Prev
- 1
- Next